Literature DB >> 32280104

Cerebrospinal Fluid/Plasma Albumin Ratio as a Biomarker for Blood-Brain Barrier Impairment Across Neurodegenerative Dementias.

Christian Sandøe Musaeus1, Helena Sophia Gleerup1, Peter Høgh2,3, Gunhild Waldemar1, Steen Gregers Hasselbalch1, Anja Hviid Simonsen1.   

Abstract

BACKGROUND: Previous studies have shown an association between disruption of the blood-brain-barrier (BBB) and dementias of different etiologies. The protein concentration of cerebrospinal fluid (CSF) can be used as an indirect measurement for the permeability of the BBB using the CSF/plasma albumin quotient (Q-Alb) or total CSF protein.
OBJECTIVE: In the current study, we wanted to investigate Q-Alb and CSF protein concentration in dementias of different etiologies and the possible confounding factors.
METHODS: A total of 510 patients and healthy controls were included in the current study. The patients were diagnosed with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), vascular dementia (VaD), or frontotemporal dementia (FTD).
RESULTS: We found that Q-Alb was significantly different between the groups (p = 0.002, F = 3.874). Patients with DLB and VaD showed the largest Q-Alb. Although not significant for CSF total protein, we found the same overall pattern for DLB and VaD. When examining confounding factors, we found a positive association with age and a lower Fazekas score in DLB as compared to VaD.
CONCLUSION: These results suggest that Q-Alb can contribute to our understanding of the pathophysiological mechanisms in DLB, and Q-Alb may serve as a supplementary diagnostic marker. Furthermore, we found a positive association with age, which may be due to differences in vascular co-morbidities. In addition, in patients with DLB, the increased Q-Alb is not due to vascular lesions. Studies are needed to validate the possible diagnostic value of Q-Alb in a larger cohort.

Entities:  

Keywords:  Alzheimer’s disease; CSF/plasma albumin quotient; Lewy body dementia; Q-Alb; albumin; cerebrospinal fluid; frontotemporal dementia; protein; vascular dementia

Mesh:

Substances:

Year:  2020        PMID: 32280104     DOI: 10.3233/JAD-200168

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  10 in total

1.  Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.

Authors:  Jennifer Taylor; Margaret Parker; Cameron P Casey; Sean Tanabe; David Kunkel; Cameron Rivera; Henrik Zetterberg; Kaj Blennow; Robert A Pearce; Richard C Lennertz; Robert D Sanders
Journal:  Br J Anaesth       Date:  2022-02-08       Impact factor: 11.719

Review 2.  Common Shared Pathogenic Aspects of Small Vessels in Heart and Brain Disease.

Authors:  Rita Moretti; Milijana Janjusevic; Alessandra Lucia Fluca; Riccardo Saro; Giulia Gagno; Alessandro Pierri; Laura Padoan; Luca Restivo; Agnese Derin; Antonio Paolo Beltrami; Paola Caruso; Gianfranco Sinagra; Aneta Aleksova
Journal:  Biomedicines       Date:  2022-04-27

Review 3.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

4.  Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin.

Authors:  Melod Mehdipour; Colin Skinner; Nathan Wong; Michael Lieb; Chao Liu; Jessy Etienne; Cameron Kato; Dobri Kiprov; Michael J Conboy; Irina M Conboy
Journal:  Aging (Albany NY)       Date:  2020-05-30       Impact factor: 5.682

Review 5.  Small Vessel Disease: Ancient Description, Novel Biomarkers.

Authors:  Rita Moretti; Paola Caruso
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

6.  Altered expression of costimulatory molecules in dementias.

Authors:  Stefan Busse; Franz von Hoff; Enrico Michler; Roland Hartig; Bernhard Bogerts; Mandy Busse
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-24       Impact factor: 5.760

Review 7.  Biomarkers for Alzheimer's Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation.

Authors:  Jeffrey Cummings; Jefferson Kinney
Journal:  Medicina (Kaunas)       Date:  2022-07-19       Impact factor: 2.948

8.  Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer's Disease.

Authors:  Qing-Qing Tao; Rong-Rong Lin; Yi-He Chen; Zhi-Ying Wu
Journal:  Aging Dis       Date:  2022-10-01       Impact factor: 9.968

9.  Characterization of the Cerebrospinal Fluid Proteome in Patients with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Diana A Abbasi; Thu T A Nguyen; Deborah A Hall; Erin Robertson-Dick; Elizabeth Berry-Kravis; Stephanie M Cologna
Journal:  Cerebellum       Date:  2021-05-27       Impact factor: 3.847

10.  Sex difference in cerebrospinal fluid/blood albumin quotients in patients with schizophreniform and affective psychosis.

Authors:  Sophie Meixensberger; Karl Bechter; Rick Dersch; Bernd Feige; Simon Maier; Miriam A Schiele; Kimon Runge; Dominik Denzel; Kathrin Nickel; Derek Spieler; Horst Urbach; Harald Prüss; Katharina Domschke; Ludger Tebartz van Elst; Dominique Endres
Journal:  Fluids Barriers CNS       Date:  2020-11-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.